Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01088048 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 241
- Enrollment target
NCT01088048 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 241 participants.
The verdict
NCT01088048, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 241 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL).
Interventions
- DRUG Fludarabine
- DRUG Rituximab
- DRUG Bendamustine
- DRUG Idelalisib
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2010-03-25 |
| Est. Completion | 2015-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01088048
The ClinicalTrials.gov registry entry for NCT01088048 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT01088048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01088048 about?
NCT01088048 is a clinical study titled "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia". The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in partic...
What is the current status of trial NCT01088048?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 241 participants. The study started on 2010-03-25. Estimated completion is 2015-04-28.
What interventions are being tested in trial NCT01088048?
The interventions under investigation include: Fludarabine (DRUG), Rituximab (DRUG), Bendamustine (DRUG), Idelalisib (DRUG), Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01088048?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.